Cisplatin 1 mg/ml Concentrate for Solution for Infusion clinical trials
5 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after Targeted therapies
This study looks at a new combination of existing medicines for a type of lung cancer (NSCLC) that has worsened after previous treatments. It aims to see how many patients respond positively to this new treatment approach.
For: Lung Cancer · NSCLCFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
A RANDOMIZED, PHASE 2, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY OF DOSTARLIMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY IN METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
This study looks at new treatments for a type of lung cancer that has spread. It compares two different drug combinations, both including chemotherapy, to see which works better at shrinking tumours and helping people live longer. It's a key step in finding improved care.
For: Lung Cancer · Non-Small CellGermany · Romania · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Global, Randomized, Phase 3, Open-Label Study of REGN2810 (Anti-PD-1 Antibody) versus Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic PD-L1 + Non-Small Cell Lung Cancer
This study looks at a new drug (REGN2810) compared to standard chemotherapy for advanced non-small cell lung cancer. It aims to see if the new drug helps people live longer and stops cancer from growing, especially for those whose cancer has a specific protein called PD-L1.
For: Non-small Cell Lung CancerCzechia · Poland · Greece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti- PD-1 Antibody) and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
This study is testing new combinations of anti-cancer medicines for people with advanced non-small cell lung cancer. It aims to see if these new approaches can help people live longer and improve their quality of life, compared to standard treatments.
For: Non-small Cell Lung CancerFrance · Poland · Ireland - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Durvalumab (MEDI4736 ) plus tremelimumab in resectable, locally advanced squamous cell carcinoma of the oral cavity: a window of opportunity study
This study looks at new drug combinations before surgery for a type of mouth cancer. Researchers want to see if these drugs can boost the body's immune response inside the cancer. It's an early-stage study to understand if these treatments could be helpful and safe for patients.
For: Resectable · locally advanced squamous cell carcinoma of the oral cavity.Belgium